British drug major GSK plc (GSK,GSK.L) announced Friday that the US Food and Drug Administration or FDA, has expanded the approved age indication of Arexvy (Respiratory Syncytial Virus vaccine, [adjuvanted]) to adults aged 18 to 49 years at increased risk for lower respiratory tract disease (LRTD) caused by RSV.
GSK's RSV vaccine was previously approved in the US for the prevention of RSV-related LRTD in adults aged 60 and older, and adults aged 50-59 at increased risk for LRTD caused by RSV. This vaccine is not for use in pregnant individuals.
The annual RSV burden among US adults aged 18-49 years is about 17,000 hospitalisations, 277,000 emergency department admissions, and 1.97 million outpatient visits.
The FDA's decision was supported by data from a Phase IIIb trial (NCT06389487), demonstrating a non-inferior immune response compared to adults aged 60 years and above. Vaccine efficacy was demonstrated in the earlier Phase III trial (NCT04886596).
The safety profile was consistent with findings from the broader Phase III programme that supported the initial US approval.
GSK continues to advance regulatory submissions for its RSV vaccine across multiple geographies to expand availability and support long-term growth objectives.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.